Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) Equity Ratio (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Equity Ratio for 9 consecutive years, with 0.88 as the latest value for Q3 2025.

  • On a quarterly basis, Equity Ratio fell 3.24% to 0.88 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.88, a 3.24% decrease, with the full-year FY2024 number at 0.89, changed 0.16% from a year prior.
  • Equity Ratio was 0.88 for Q3 2025 at Denali Therapeutics, roughly flat from 0.88 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.92 in Q2 2024 to a low of 0.66 in Q3 2022.
  • A 5-year average of 0.8 and a median of 0.88 in 2025 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: fell 15.33% in 2021, then surged 36.82% in 2023.
  • Denali Therapeutics' Equity Ratio stood at 0.69 in 2021, then rose by 4.17% to 0.71 in 2022, then increased by 25.15% to 0.89 in 2023, then increased by 0.16% to 0.89 in 2024, then decreased by 1.95% to 0.88 in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Equity Ratio are 0.88 (Q3 2025), 0.88 (Q2 2025), and 0.88 (Q1 2025).